Name: 글로벌 경피 약물 전달 장치 시장 - 2022-2029 - Prime research
SKU: DMMD49
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 경피 약물 전달 장치 시장 규모는 2022년 XX백만 달러였으며, 2029년까지 XX백만 달러에 이를 것으로 예상되며, 예측 기간(2022-2029년) 동안 연평균 성장률(CAGR)은 XX%입니다.
약물 전달 장치는 약물 또는 치료제를 전달하는 데 사용되는 특수 장비입니다. 경피 약물 전달 장치는 피부에 부착하여 특정 용량의 약물을 혈류로 전달하는 약물 접착 패치를 사용합니다.
시장 동향
전 세계 경피 약물 전달 장치 시장 성장을 견인하는 주요 요인은 전 세계적으로 증가하는 질병 발생률, 연구 개발 투자 증가, 그리고 경피 약물 전달 장치의 장점에 대한 대중의 인식 제고입니다. 신제품 출시 증가는 경피 약물 전달 장치 시장 성장에 기여합니다.
경피 약물 전달 시스템의 적용 분야 확대와 새로운 연구 증가는 시장 성장을 촉진할 것으로 예상됩니다.

신경계 질환이나 심혈관 질환 등 다양한 만성 질환 치료에 경피 약물 전달 장치의 사용이 증가하고 있으며, 신제품 출시가 늘어나면서 경피 약물 전달 장치 시장이 성장하고 있습니다. 전 세계적으로 질병 발생률이 증가하는 추세 또한 시장 성장에 기여하고 있습니다. 많은 의료 기업들이 신제품 개발을 위해 연구 개발 활동을 강화하고 있습니다.
경피 약물 전달 장치는 간 초회 통과 효과를 회피하고 투약 빈도를 줄이며 환자 순응도를 높이는 등 다른 투여 경로에 비해 여러 가지 이점을 제공합니다. 다양한 질병의 증가로 인해 전 세계적으로 이러한 패치 시장이 성장하고 있습니다. 또한, 새로운 패치에 대한 연구 개발 증가와 주요 기업들의 기술적으로 진보된 제품 출시 또한 시장 성장에 중요한 역할을 할 것으로 예상됩니다.
다양한 신제품 출시, 규제 승인 및 연구 결과 발표는 시장 성장에 기여하고 있습니다. 예를 들어, 2022년 10월 17일에는 노벤 파마슈티컬스(Noven Pharmaceuticals)가 신제품을 출시했습니다. 히사미츠 제약의 완전 자회사이자 경피 치료제 개발에 주력하는 Inc.는 미국 정신간호사협회(APNA) 제36회 연례 학술대회에서 새로운 두 가지 약물동태학(PK) 모델링 데이터셋 결과를 발표한다고 밝혔습니다. 이 데이터는 각각 주의력결핍 과잉행동장애(ADHD) 치료를 위한 덱스트로암페타민 경피 시스템(d-ATS)의 가변 착용 시간 연구와 소아 환자에서 성인으로의 d-ATS 효능 외삽에 대한 결과를 보여줍니다.
경피 약물 전달 장치와 관련된 한계점들이 시장 성장을 저해할 것으로 예상됩니다.
그러나 경피 약물 전달 패치의 가장 큰 한계는 친유성, 소형, 저용량 약물만 전달할 수 있다는 점입니다. 분자량이 크고(500달톤 이상) 친수성인 약물의 피부 최외층을 통한 전달은 매우 제한적입니다. 능동 전달 시스템은 전달 범위를 향상시킬 수 있지만 외부 전원 공급 장치가 필요하고 기기가 부피가 크다는 단점이 있습니다.
제품이 리콜될 경우, 결함 있는 제품을 회수하고 교체하는 과정에서 기업이나 제조업체는 막대한 손실을 입을 수 있습니다. 이러한 막대한 손실은 매출과 시장 점유율에 영향을 미쳐 전체 시장에 악영향을 미칩니다. 핵심 과제는 기술 자체보다는 제약과 의료기기라는 두 개의 서로 다른 세계를 통합하는 데 있습니다.
COVID-19 영향 분석
팬데믹은 전 세계적인 재정 전망, 운영 및 위기 대응 전략에 부정적인 영향을 미쳤습니다. COVID-19 발생은 의료 산업에 심각한 타격을 입혔습니다. 경피 약물 전달 장치 시장은 COVID-19로 인해 다양한 연구 및 임상 시험이 연기되면서 막대한 손실을 입었습니다. 전 세계적으로 COVID-19 및 그 변이 바이러스의 확산을 막기 위한 백신 개발의 시급성으로 관심이 집중되었습니다. 전 세계적으로 다양한 계획, 제품 출시, 혁신, 협력 및 합병이 진행되면서 시장 성장이 촉진되고 있습니다. 예를 들어, 2020년 4월 13일, 히사미츠 제약(Hisamitsu Pharmaceutical Co., Inc.)의 완전 자회사인 노벤 제약(Noven Pharmaceuticals, Inc.)은 미국 식품의약국(FDA)의 승인을 받은 정신분열증 환자 치료제 세쿠아도(SECUADO, 아세나핀) 경피 투여 시스템이 미국에서 처방전을 통해 구입 가능하다고 발표했습니다.
세그먼트 분석
마이크로니들 패치 부문은 예측 기간(2022-2029년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
마이크로니들 패치 부문은 전 세계 경피 약물 전달 장치 시장에서 가장 큰 시장 점유율을 차지하고 있습니다. 전 세계 경피 약물 전달 장치 시장은 제품 유형에 따라 리저버 패치, 매트릭스 패치, 약물 함유 접착 패치 및 마이크로니들 패치로 구분됩니다. 마이크로니들 패치 부문은 우수한 장점, 효능 및 결과, 치료 대상 질환의 증가, 그리고 이러한 경피 약물 전달 장치의 채택 증가로 인해 가장 큰 시장 점유율을 차지하고 있습니다.

미세침(세라믹과 실리콘으로 구성)이 피부 조직을 뚫는 마이크로니들 패치는 미세한 구멍을 만들어 약물 활성 성분이 통과할 수 있도록 합니다. 마이크로니들 패치는 일반적으로 고체형, 용해형, 코팅형, 속이 빈 마이크로니들 패치의 네 가지 유형으로 분류됩니다. 고체형 패치는 피부에 미세한 구멍을 만들기 위한 전처리 단계로 사용됩니다. 코팅형 패치는 미세침을 피부에 직접 적용하여 바늘 표면에서 약물이 용해되어 체내로 흡수되도록 합니다. 용해형 마이크로니들은 생분해성 고분자로 만들어진 미세침에 약물을 탑재한 형태입니다.
규제 승인 증가, 기술 발전, 신제품 출시, 연구/임상 시험 진행 등이 마이크로니들 시장의 성장을 견인하고 있습니다. 예를 들어, 2022년 12월 2일, 자이더스 라이프사이언스(Zydus Lifesciences Limited)는 미국 식품의약국(USFDA)으로부터 에스트라디올 경피 시스템 USP의 시판 승인을 받았다고 발표했습니다. 에스트라디올은 여성의 갱년기 증상인 목과 가슴의 열감, 심한 열감, 질 건조증 등을 치료하는 데 사용됩니다. 이 약은 인도 아메다바드에 있는 자이더스 라이프사이언스의 제형 제조 시설에서 생산될 예정입니다.
지역 분석
북미는 전 세계 경피 약물 전달 장치 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
북미는 인구 규모, 우수한 의료 인프라, 질병 발생률 증가 등으로 인해 전 세계 경피 약물 전달 장치 시장을 주도하고 있습니다. 미국 내 의료비 지출 증가로 인해 시장은 예측 기간 동안 비교적 높은 성장률을 보일 것으로 예상됩니다. 시장 규모의 상당 부분은 높은 의료비 지출에 기인합니다.
의료비 지출 증가와 사람들의 인식 제고 또한 이 지역 시장 성장에 기여하고 있습니다. 리저버 패치, 매트릭스 패치, 약물 함유 접착 패치, 마이크로니들 패치와 같은 제품의 발전, 이 지역의 제약 회사 증가, 정부 승인 및 주요 업체들의 존재는 경피 약물 전달 장치 시장의 성장에 기여하고 있습니다.
또한, 제품 출시 건수의 증가는 시장 성장의 원동력입니다. 이 지역에서는 많은 주요 개발, 규제 승인, 기술 발전, 협력 및 계약이 이루어지고 있습니다. 예를 들어, 2022년 3월 23일, 히사미츠 제약의 완전 자회사인 노벤 제약은 성인 및 소아 주의력 결핍 과잉 행동 장애(ADHD) 환자 치료를 위한 XELSTRYM(덱스트로암페타민) 경피 시스템(CII)에 대해 미국 식품의약국(FDA)의 승인을 받았다고 발표했습니다. XELSTRYM은 FDA 승인을 받은 유일한 경피 암페타민 패치입니다.

경쟁 환경
경피 약물 전달 장치 시장은 국내외 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 주요 기업으로는 Novartis AG, Zydus Lifesciences Ltd, Boehinger Ingelheim International GmbH, AbbVie (Allergan), UCB S.A., Viatris Inc., Noven Pharmaceuticals, Inc., Acrux Limited, Purdue Pharma L.P., Endo International plc 등이 있습니다. 이들 기업은 신제품 출시, 인수합병, 파트너십, 협력 등 다양한 성장 전략을 통해 시장 성장에 기여하고 있습니다. 예를 들어, 2022년 1월 5일 Endo International plc는 자회사인 Endo Ventures Limited가 Radius Health, Inc.와 캐나다에서 아발로파라티드(abaloparatide)를 상용화 및 유통하기 위한 계약을 체결했다고 발표했습니다. 이 계약에 따라 Endo는 현재 임상 개발 중인 새로운 제형인 아발로파라티드 경피 패치(abaloparatide-TD)에 대한 권리를 획득했습니다.

Novartis AG.

개요: 노바티스는 다양한 의약품 및 제네릭 의약품의 발견, 개발, 제조 및 판매에 참여하고 있습니다. 이 회사는 전 세계적으로 혁신 의약품 사업부와 바이오시밀러 및 제네릭 의약품 사업부인 산도즈(Sandoz)의 두 가지 사업부를 운영하고 있습니다.
제품 포트폴리오:
엑셀론 패치: 엑셀론 패치는 알츠하이머병(AD) 및 파킨슨병(PD) 관련 치매 치료에 사용되는 리바스티그민 경피 패치입니다.
이 글로벌 경피 약물 전달 장치 시장 보고서는 약 45개 이상의 시장 데이터 표, 40개 이상의 그림 및 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
The global transdermal drug delivery devices market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).
Drug delivery devices are specialized equipment used for the delivery of a drug or therapeutic agent. A transdermal drug delivery device uses a medicated adhesive skin patch that is placed on the skin to deliver a specific dose of medication into the bloodstream.
Market- Dynamics
The major factors driving the global transdermal drug delivery devices market are an increase in the number of diseases globally, rising research and development expenditure and awareness among the population regarding the advantages of transdermal drug delivery devices. An increase in novel product launches contributes to the growth of the transdermal drug delivery devices market.
The expanding areas of application of transdermal drug delivery systems and rising novel research studies are expected to drive the market’s growth.
The rising adoption of these transdermal drug delivery devices for the treatment of various chronic diseases, such as neurological or cardiovascular disorders, and many more and the rising number of novel product launches drive the transdermal drug delivery devices market. An increase in diseases globally is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.
The transdermal drug delivery devices are used for the advantages it provides over other route of administration drug delivery such as avoiding hepatic first-pass effect reduced dosing frequency and better patient compliance. The market for these patches is increasing worldwide due to the increasing number of different diseases. Moreover, the increase in research and development of novel patches and the availability of technologically advanced products by key players are also expected to play a vital role in the market’s growth.
Various novel product launches, regulatory approvals and research studies contribute to the market’s growth. For instance, in October 17, 2022, Noven Pharmaceuticals. Inc., Hisamitsu Pharmaceutical Co., Inc.’s wholly owned subsidiary, focusing on the transdermal therapy development, announced about presenting its novel two pharmacokinetic (PK) modeling datasets results at the 36th annual conference of American Psychiatric Nurses Association (APNA). The data shows the investigation of dextroamphetamine transdermal system’s (d-ATS) variable wear times for the Attention-Deficit/Hyperactivity Disorder (ADHD) treatment and d-ATS efficacy extrapolation from pediatric patients to adults respectively.
The limitations associated with transdermal drug delivery devices are expected to hamper the market’s growth.
However, the major limitation of transdermal drug delivery patches is that they can deliver only lipophilic, small and low-dose drugs. The high molecular weight (more than 500 Dalton) and hydrophilic drug delivery via the skin’s outermost layer are highly restrained. The active delivery system can enhance the extent of transmission, but it requires an external power supply, and the devices are bulky as well.
If a product is recalled, the process of retrieving and replacing the defective product may cause a company or a manufacturer to incur huge losses associated with replacing and fixing faulty products. These huge losses will affect the revenue and the company's market share, which will impact the overall market. The key challenges are less about the technology itself and more about integrating two distinct world's pharma and medical device.
COVID-19 Impact Analysis
The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The transdermal drug delivery devices market has experienced huge losses due to COVID, as various research and clinical trials got postponed. An urgent need for vaccines to prevent the spreading of COVID and its variant across the globe diverted the attention. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in April 13, 2020, Noven Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc.’s wholly owned subsidiary, announced that its SECUADO (asenapine) transdermal system, approved for the treatment of schizophrenia patients by the U.S. Food and Drug Administration (FDA), is now available in the U.S. by prescription.
Segment Analysis
The micro-needle patch segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The micro-needle patch segment is the highest market holder in the global transdermal drug delivery devices market. The global transdermal drug delivery devices market is segmented based on product type: reservoir patch, matrix patch, drug-in adhesive patch and micro-needle patch. The micro-needle patch segment is the largest market shareholder due to its better advantage, efficacy and results, increasing diseases and rising adoption of these transdermal drug delivery devices.
In micro-needle patch with the sharp micro-needles (made up of ceramics and silicon) the skin tissues are pierced. As a result, there is a formation of micro-scale perforation. The perforated surface provides the pharmaceutical active ingredient passage. The micro-needle patch generally is categorized into four types: solid micro-needle, dissolving micro-needle, coated micro-needle, and hollow micro-needle patches. The solid ones are utilized as a pre-treatment for skin to develop micro-scale pores. In coated one micro-needle are directly applied to the skin, from the needle’s surface the drug dissolves off and eventually transfers to the body. The dissolving micro-needles are the ones in which drugs are loaded in micro-needles formed of biodegradable polymer.
The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market’s growth. For instance, in December 2, 2022, Zydus Lifesciences Limited announced its approval for Estradiol Transdermal System USP marketing, by the United States Food and Drug Administration (USFDA). Estradiol is utilized for treating menopause symptoms like hot feelings in the neck and chest or strong feelings of heat and vaginal dryness in women. The drug will be produced at the formulation manufacturing site of Zydus Lifesciences at Ahmedabad, India.
Geographical Analysis
North America holds the largest market share in the global transdermal drug delivery devices market.
North America dominates the global transdermal drug delivery devices market, primarily due to its large population, excellent medical infrastructure, and rising number of diseases. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market’s significant size is attributed to the high medical expenditure.
Increasing expenditure on healthcare and raising awareness among people is also contributing to the market’s growth in this region. Advancement of products such as reservoir patch, matrix patch, drug-in adhesive patch, micro-needle patch, increase in pharmaceutical establishment across the region and government approvals and the presence of key players in the region are contributing to the growth of the transdermal drug delivery devices market.
Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in March 23, 2022, Noven Pharmaceuticals, Inc., Hisamitsu Pharmaceutical Co., Inc.’s wholly-owned subsidiary, announced that the approval of XELSTRYM (dextroamphetamine) transdermal system, CII from the U.S. Food and Drug Administration (FDA) for Attention-Deficit/Hyperactivity Disorder (ADHD) treatment for adults and pediatric patients. XELSTRYM is the only transdermal amphetamine patch which received FDA-approval.
Competitive Landscape
The transdermal drug delivery devices market is moderately competitive with local and global companies’ presence. Novartis AG, Zydus Lifesciences Ltd, Boehinger Ingelheim International GmbH, AbbVie (Allergan), UCB S.A., Viatris Inc., Noven Pharmaceuticals, Inc., Acrux Limited, Purdue Pharma L.P., Endo International plc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in January 5, 20221, Endo International plc announced that Endo Ventures Limited, its subsidiary has entered into agreements with Radius Health, Inc. to commercialize and distribute abaloparatide in Canada. Under the agreement, Endo got the rights to abaloparatide-transdermal patch (abaloparatide-TD), a novel formulation currently undergoing clinical development.
Novartis AG.
Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.
Product Portfolio:
EXELON PATCH: Exelon Patch is a rivastigmine transdermal patch indicated for dementia of the Alzheimer’s type (AD) and dementia linked with Parkinson’s disease (PD).
The global transdermal drug delivery devices market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Expanding areas of application of transdermal drug delivery systems
4.1.1.2. Surge in novel product launches
4.1.1.3. Increasing incidence of infectious diseases
4.1.2. Restraints:
4.1.2.1. Limitations associated with transdermal drug delivery devices
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Reservoir Patch *
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Matrix Patch
7.4. Drug-in Adhesive Patch
7.5. Micro-needle Patch
8. By Technology
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. Passive Transdermal Technology *
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.2.3. Chemical Enhancers
8.2.4. Prodrug
8.2.5. Eutectic Systems
8.3. Active Transdermal Technology
8.3.1. Radiofrequency Ablation
8.3.2. Laser Thermal Ablation
8.3.3. Electroporation
8.3.4. Iontophoresis
8.3.5. Microneedle
8.3.6. Jet Injector
8.3.7. Ultrasound
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Pain Management *
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Hormone Replacement Therapy
9.4. Contraception
9.5. Neurological Disorders
9.6. Smoking Cessation
9.7. Cardiovascular Disorders
9.8. Diabetes
9.9. Others
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals *
10.2.1. Introduction
10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Ambulatory Surgical Centers
10.4. Homecare Setting
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Products Benchmarking
12.4. List of Key Companies to Watch
13. Company Profiles
13.1. Novartis *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Zydus Lifesciences Ltd
13.3. Boehinger Ingelheim International GmbH
13.4. AbbVie (Allergan)
13.5. UCB S.A.
13.6. Viatris Inc.
13.7. Noven Pharmaceuticals, Inc.
13.8. Acrux Limited
13.9. Purdue Pharma L.P.
13.10. Endo International plc
LIST NOT EXHAUSTIVE
14. Global Transdermal Drug Delivery Devices Market – DataM
14.1. Appendix
14.2. About Us and End-User
14.3. Contact Us

언급된 주요 기업들

Novartis, Zydus Lifesciences Ltd, Boehinger Ingelheim International GmbH, AbbVie (Allergan), UCB S.A., Viatris Inc., Noven Pharmaceuticals, Inc., Acrux Limited, Purdue Pharma L.P., Endo International plc

표 목록 (Tables)

List of Tables

Table 1 Global Transdermal Drug Delivery Devices Market Value, By Product Type, 2023, 2027 & 2031 ($ Million)

Table 2 Global Transdermal Drug Delivery Devices Market Value, By Technology, 2023, 2027 & 2031 ($ Million)

Table 3 Global Transdermal Drug Delivery Devices Market Value, By Application, 2023, 2027 & 2031 ($ Million)

Table 4 Global Transdermal Drug Delivery Devices Market Value, By End-User, 2023, 2027 & 2031 ($ Million)

Table 5 Global Transdermal Drug Delivery Devices Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 6 Global Transdermal Drug Delivery Devices Market Value, By Product Type, 2023, 2027 & 2031 ($ Million)

Table 7 Global Transdermal Drug Delivery Devices Market Value, By Product Type, 2022-2031 ($ Million)

Table 8 Global Transdermal Drug Delivery Devices Market Value, By Technology, 2023, 2027 & 2031 ($ Million)

Table 9 Global Transdermal Drug Delivery Devices Market Value, By Technology, 2022-2031 ($ Million)

Table 10 Global Transdermal Drug Delivery Devices Market Value, By Application, 2023, 2027 & 2031 ($ Million)

Table 11 Global Transdermal Drug Delivery Devices Market Value, By Application, 2022-2031 ($ Million)

Table 12 Global Transdermal Drug Delivery Devices Market Value, By End-User, 2023, 2027 & 2031 ($ Million)

Table 13 Global Transdermal Drug Delivery Devices Market Value, By End-User, 2022-2031 ($ Million)

Table 14 Global Transdermal Drug Delivery Devices Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 15 Global Transdermal Drug Delivery Devices Market Value, By Region, 2022-2031 ($ Million)

Table 16 North America Transdermal Drug Delivery Devices Market Value, By Product Type, 2022-2031 ($ Million)

Table 17 North America Transdermal Drug Delivery Devices Market Value, By Technology, 2022-2031 ($ Million)

Table 18 North America Transdermal Drug Delivery Devices Market Value, By Application, 2022-2031 ($ Million)

Table 19 North America Transdermal Drug Delivery Devices Market Value, By End-User, 2022-2031 ($ Million)

Table 20 North America Transdermal Drug Delivery Devices Market Value, By Country, 2022-2031 ($ Million)

Table 21 South America Transdermal Drug Delivery Devices Market Value, By Product Type, 2022-2031 ($ Million)

Table 22 South America Transdermal Drug Delivery Devices Market Value, By Technology, 2022-2031 ($ Million)

Table 23 South America Transdermal Drug Delivery Devices Market Value, By Application, 2022-2031 ($ Million)

Table 24 South America Transdermal Drug Delivery Devices Market Value, By End-User, 2022-2031 ($ Million)

Table 25 South America Transdermal Drug Delivery Devices Market Value, By Country, 2022-2031 ($ Million)

Table 26 Europe Transdermal Drug Delivery Devices Market Value, By Product Type, 2022-2031 ($ Million)

Table 27 Europe Transdermal Drug Delivery Devices Market Value, By Technology, 2022-2031 ($ Million)

Table 28 Europe Transdermal Drug Delivery Devices Market Value, By Application, 2022-2031 ($ Million)

Table 29 Europe Transdermal Drug Delivery Devices Market Value, By End-User, 2022-2031 ($ Million)

Table 30 Europe Transdermal Drug Delivery Devices Market Value, By Country, 2022-2031 ($ Million)

Table 31 Asia-Pacific Transdermal Drug Delivery Devices Market Value, By Product Type, 2022-2031 ($ Million)

Table 32 Asia-Pacific Transdermal Drug Delivery Devices Market Value, By Technology, 2022-2031 ($ Million)

Table 33 Asia-Pacific Transdermal Drug Delivery Devices Market Value, By Application, 2022-2031 ($ Million)

Table 34 Asia-Pacific Transdermal Drug Delivery Devices Market Value, By End-User, 2022-2031 ($ Million)

Table 35 Asia-Pacific Transdermal Drug Delivery Devices Market Value, By Country, 2022-2031 ($ Million)

Table 36 Middle East & Africa Transdermal Drug Delivery Devices Market Value, By Product Type, 2022-2031 ($ Million)

Table 37 Middle East & Africa Transdermal Drug Delivery Devices Market Value, By Technology, 2022-2031 ($ Million)

Table 38 Middle East & Africa Transdermal Drug Delivery Devices Market Value, By Application, 2022-2031 ($ Million)

Table 39 Middle East & Africa Transdermal Drug Delivery Devices Market Value, By End-User, 2022-2031 ($ Million)

Table 40 Novartis AG: Overview

Table 41 Novartis AG: Product Portfolio

Table 42 Novartis AG: Key Developments

Table 43 Zydus Lifesciences Ltd: Overview

Table 44 Zydus Lifesciences Ltd: Product Portfolio

Table 45 Zydus Lifesciences Ltd: Key Developments

Table 46 Boehinger Ingelheim International GmbH: Overview

Table 47 Boehinger Ingelheim International GmbH: Product Portfolio

Table 48 Boehinger Ingelheim International GmbH: Key Developments

Table 49 AbbVie (Allergan): Overview

Table 50 AbbVie (Allergan): Product Portfolio

Table 51 AbbVie (Allergan): Key Developments

Table 52 UCB S.A.: Overview

Table 53 UCB S.A.: Product Portfolio

Table 54 UCB S.A.: Key Developments

Table 55 Viatris Inc.: Overview

Table 56 Viatris Inc.: Product Portfolio

Table 57 Viatris Inc.: Key Developments

Table 58 Noven Pharmaceuticals, Inc.: Overview

Table 59 Noven Pharmaceuticals, Inc.: Product Portfolio

Table 60 Noven Pharmaceuticals, Inc.: Key Developments

Table 61 Acrux Limited: Overview

Table 62 Acrux Limited: Product Portfolio

Table 63 Acrux Limited: Key Developments

Table 64 Purdue Pharma L.P.: Overview

Table 65 Purdue Pharma L.P.: Product Portfolio

Table 66 Purdue Pharma L.P.: Key Developments

Table 67 Endo International plc: Overview

Table 68 Endo International plc: Product Portfolio

Table 69 Endo International plc: Key Development

그림 목록 (Figures)

List of Figures

Figure 1 Global Transdermal Drug Delivery Devices Market Share, By Product Type, 2022 & 2031 (%)

Figure 2 Global Transdermal Drug Delivery Devices Market Share, By Technology, 2022 & 2031 (%)

Figure 3 Global Transdermal Drug Delivery Devices Market Share, By Application, 2022 & 2031 (%)

Figure 4 Global Transdermal Drug Delivery Devices Market Share, By End-User, 2022 & 2031 (%)

Figure 5 Global Transdermal Drug Delivery Devices Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 7 Global Transdermal Drug Delivery Devices Market Y-o-Y Growth, By Product Type, 2022-2031 (%)

Figure 8 Reservoir Patch: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 9 Matrix Patch: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 10 Drug-in Adhesive Patch: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 11 Micro-needle Patch: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 12 Global Transdermal Drug Delivery Devices Market Y-o-Y Growth, By Technology, 2022-2031 (%)

Figure 13 Passive Transdermal Technology: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 14 Active Transdermal Technology: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 15 Global Transdermal Drug Delivery Devices Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure 16 Pain Management: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 17 Hormone Replacement Therapy: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 18 Contraception: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 19 Neurological Disorders: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 20 Smoking Cessation: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 21 Cardiovascular Disorders: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 22 Others: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 23 Global Transdermal Drug Delivery Devices Market Y-o-Y Growth, By End-User, 2022-2031 (%)

Figure 24 Hospitals: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 25 Ambulatory Surgical Centers: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 26 Homecare Setting: Global Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 27 Global Transdermal Drug Delivery Devices Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 28 North America Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 29 North America Transdermal Drug Delivery Devices Market Share, By Product Type, 2022 & 2031 (%)

Figure 30 North America Transdermal Drug Delivery Devices Market Share, By Technology, 2022 & 2031 (%)

Figure 31 North America Transdermal Drug Delivery Devices Market Share, By Application, 2022 & 2031 (%)

Figure 32 North America Transdermal Drug Delivery Devices Market Share, By End-User, 2022 & 2031 (%)

Figure 33 North America Transdermal Drug Delivery Devices Market Share, By Country, 2022 & 2031 (%)

Figure 34 South America Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 35 South America Transdermal Drug Delivery Devices Market Share, By Product Type, 2022 & 2031 (%)

Figure 36 South America Transdermal Drug Delivery Devices Market Share, By Technology, 2022 & 2031 (%)

Figure 37 South America Transdermal Drug Delivery Devices Market Share, By Application, 2022 & 2031 (%)

Figure 38 South America Transdermal Drug Delivery Devices Market Share, By End-User, 2022 & 2031 (%)

Figure 39 South America Transdermal Drug Delivery Devices Market Share, By Country, 2022 & 2031 (%)

Figure 40 Europe Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 41 Europe Transdermal Drug Delivery Devices Market Share, By Product Type, 2022 & 2031 (%)

Figure 42 Europe Transdermal Drug Delivery Devices Market Share, By Technology, 2022 & 2031 (%)

Figure 43 Europe Transdermal Drug Delivery Devices Market Share, By Application, 2022 & 2031 (%)

Figure 44 Europe Transdermal Drug Delivery Devices Market Share, By End-User, 2022 & 2031 (%)

Figure 45 Europe Transdermal Drug Delivery Devices Market Share, By Country, 2022 & 2031 (%)

Figure 46 Asia-Pacific Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 47 Asia-Pacific Transdermal Drug Delivery Devices Market Share, By Product Type, 2022 & 2031 (%)

Figure 48 Asia-Pacific Transdermal Drug Delivery Devices Market Share, By Technology, 2022 & 2031 (%)

Figure 49 Asia-Pacific Transdermal Drug Delivery Devices Market Share, By Application, 2022 & 2031 (%)

Figure 50 Asia-Pacific Transdermal Drug Delivery Devices Market Share, By End-User, 2022 & 2031 (%)

Figure 51 Asia-Pacific Transdermal Drug Delivery Devices Market Share, By Country, 2022 & 2031 (%)

Figure 52 Middle East & Africa Transdermal Drug Delivery Devices Market Value, 2022-2031 ($ Million)

Figure 53 Middle East & Africa Transdermal Drug Delivery Devices Market Share, By Product Type, 2022 & 2031 (%)

Figure 54 Middle East & Africa Transdermal Drug Delivery Devices Market Share, By Technology, 2022 & 2031 (%)

Figure 55 Middle East & Africa Transdermal Drug Delivery Devices Market Share, By Application, 2022 & 2031 (%)

Figure 56 Middle East & Africa Transdermal Drug Delivery Devices Market Share, By End-User, 2022 & 2031 (%)

Figure 57 Novartis AG: Financials

Figure 58 Zydus Lifesciences Ltd: Financials

Figure 59 Boehinger Ingelheim International GmbH: Financials

Figure 60 AbbVie (Allergan): Financials

Figure 61 UCB S.A.: Financials

Figure 62 Viatris Inc.: Financials

Figure 63 Noven Pharmaceuticals, Inc.: Financials

Figure 64 Acrux Limited: Financials

Figure 65 Purdue Pharma L.P.: Financials

Figure 66 Endo International plc: Financials

글로벌 경피 약물 전달 장치 시장 – 2022-2029

Global Transdermal Drug Delivery Devices Market - 2022-2029